Advances in Gastric and GE Junction Cancer Treatment: Durvalumab Combined with FLOT Shows Promising Results at ASCO
A groundbreaking phase 3 trial shows that combining durvalumab with FLOT chemotherapy significantly improves outcomes for patients with resectable gastric and GE junction cancer, offering new hope in cancer treatment.
Recent research presented at the American Society of Clinical Oncology (ASCO) meeting highlights a significant breakthrough in the treatment of resectable gastric and gastroesophageal (GE) junction adenocarcinoma. A phase 3, double-blind clinical trial investigated the efficacy of adding durvalumab, an immunotherapy drug, to the standard FLOT chemotherapy regimen.
The study involved 948 patients who were randomly assigned to receive either durvalumab (1,500 mg) or a placebo every four weeks. The treatment plan included four cycles of the combined therapy followed by 10 additional cycles of durvalumab or placebo. The primary focus was to assess event-free survival, which measures the length of time patients remain free from disease progression or recurrence.
Findings demonstrated that patients receiving durvalumab experienced notably better outcomes. The two-year event-free survival rate was 67.4% in the durvalumab group compared to 58.5% in the placebo group. Overall survival also improved, with 75.7% of durvalumab-treated patients surviving at two years versus 70.4% in the control group. Additionally, a higher proportion of patients in the durvalumab group achieved a pathological complete response (19.2% vs. 7.2%), indicating an absence of detectable cancer after treatment.
Dr. Yelena Y. Janjigian of Memorial Sloan Kettering Cancer Center emphasized the importance of these findings, stating that this therapy combination could represent a major advancement for patients facing this challenging diagnosis. The results suggest that adding durvalumab to the FLOT regimen could significantly enhance patient outcomes, bringing hope for higher cure rates.
The study was sponsored by AstraZeneca, which manufactures durvalumab. Several authors disclosed ties to pharmaceutical companies, aligned with the industry-led nature of the research.
For more on this study, visit the published article in the New England Journal of Medicine and the ASCO annual meeting resources.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Elevated BMI Levels Increase Risk of Post-Bariatric Surgery Complications
Higher body mass index (BMI), especially over 50, significantly raises the risk of complications after bariatric surgery, according to recent research. This study provides crucial insights for improving patient safety and outcomes.
Early Childhood Weight Gain Promotes Adult Height Without Increasing Obesity Risk, New Research Finds
New research shows that weight gain during childhood, particularly in undernourished children, can lead to taller adults without increasing obesity or high blood pressure risk, emphasizing the importance of extended nutritional support.
New Insights: The Thalamus's Crucial Role in Abstract Thinking and Executive Control
Emerging research uncovers the active role of the brain's thalamus in abstract reasoning and executive functions, reshaping our understanding of cognition and potential therapies.
New Long Noncoding RNA Identified as Potential Target for Prostate Cancer Therapy
A new study identifies a specific long noncoding RNA, PRCAT71, as a potential biomarker and therapeutic target for prostate cancer, revealing new pathways for treatment.